The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.
July 18th 2025
Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.
Understand how recent advances in GLP-1 receptor agonists and other therapies are transforming the treatment of type 2 diabetes and obesity through a shift of reactive to proactive care that addresses root causes of cardiometabolic disease.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
FTC Takes Legal Action Against 3 Largest PBMs Over Insulin Costs
FDA Expands Omnipod 5 AID System Label to Treat Type 2 Diabetes